“…Another set of papers studies how different regulator objectives, such as reducing adverse selection, would theoretically translate into differently designed risk adjustment schemes (Glazer and McGuire, 2002;Breyer et al, 2011;McGuire et al, 2013;, while yet another deals with optimizing risk adjustment by incorporating new risk adjusters or innovative statistical methods 6 (van de Ven and Ellis, 2000;Manning et al, 2005;Breyer et al, 2011;Buchner et al, 2013;Lorenz, 2014;van Kleef et al, 2015;Buchner et al, 2017;Geruso and McGuire, 2016 and (iv) whether and how insurers pay for capital costs of hospitals. In contrast to the first German RAS evaluated in this paper, more sophisticated RAS' are based on regression models, high-cost diagnoses, and sometimes detailed pharmaceutical information (Juhnke et al, 2016).…”